MedTrace Logo

Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes

NCT00506298 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2009-05-13

No results posted yet for this study

Summary

This trial will assess the efficacy of CRx-401 in lowering FPG levels in patients taking metformin to treat their diabetes. In addition, this initial trial will evaluate insulin resistance (HOMA-IR index), HgbA1c levels, glycated protein, LDL, HDL, triglycerides, and total cholesterol, as well as the safety of CRx-401.

Conditions

Interventions

DRUG

bezafibrate + diflunisal

bezafibrate + diflunisal

DRUG

bezafibrate + placebo

bezafibrate + placebo

Sponsors & Collaborators

  • Zalicus

    lead INDUSTRY

Principal Investigators

  • Tim Zmijowskyj, MD · Medicor Research Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2009-04-30
Completion
2009-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00506298 on ClinicalTrials.gov